England’s NICE Turns Down Pfizer’s Talzenna In HER2-Negative Breast Cancer
Executive Summary
Pfizer’s Talzenna is not cost effective enough to be used on the National Health Service for patients with HER2-negative advanced breast cancer with inherited BRCA mutations, according to draft guidance from England’s health technology assessment body NICE.